Results 91 to 100 of about 2,348 (179)

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors

, 2014
PURPOSE: This phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor ...
D Mahalingam (7806581), Y Shou (7806584), MA Moles (7806587), CP Turtschi (7806572), AC Mita (7806605), DD Amakye (7806599), KL Rose (7806596), J Rodon (7806563), RG Stoller (7806569), J Sarantopoulos (7806578), HA Tawbi (7806566), L Yang (6502793), R Dummer (7806602), J Baselga (7806575), C Granvil (7806590), AL Thomas (7661462), E Hurh (7806593)   +16 more
core  

Efficacy and Safety of Sonidegib in the Treatment of Multiple Facial Cutaneous Basal Cell Carcinomas with Chronic Renal Insufficiency: A Case Report. [PDF]

Clin Cosmet Investig Dermatol
Jing W, Yang J, Gong Z, Lei W, Zhang Z, Rao WB, Ai Y.   +6 more
europepmc   +1 more source

Metabolic Imaging of Advanced Basal Cell Carcinoma Treated with Sonidegib: A Retrospective Case Series Study

Background: Positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (18F-FDG) is a firmly established tool in oncology and is gaining importance in dermato-oncology. However, its use in advanced basal cell carcinoma (BCC) is
Luca Filippi, Concetta Potenza, Ilaria Proietti, Oreste Bagni   +3 more
core   +1 more source

Chromatic hyper Zagreb topological descriptors and QSPR analysis of certain skin cancer drugs. [PDF]

Front Chem
Pavithra R, Ravi Sankar J.
europepmc   +1 more source

Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study

, 2018
Background: Patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC), two difficult-to-treat populations, have had limited treatment options.
Plummer, R., Yi, T., Mone, M., Dummer, R., Zhou, J., Kudchadkar, R., Guminski, A., Castro, H., Migden, M.R., Chang, A.L.S., Trefzer, U., Loquai, C., Lewis, K.D., Dirix, L., Combemale, P., Lear, J.T., Gutzmer, R., Kaatz, M., Stratigos, A., Sellami, D.   +19 more
core  

Clinical Outcomes of Sonidegib in Vismodegib-Exposed Locally Advanced Basal Cell Carcinoma: Insights From a Multicenter Descriptive Study. [PDF]

J Skin Cancer
Prados-Carmona A, Martínez-Pérez M, Velasco-Amador JP, Almazán-Fernández FM, Ruiz-Villaverde R.   +4 more
europepmc   +1 more source

Successful Alternative Administration of Sonidegib in a Patient with Gorlin-Goltz Syndrome and Dysphagia: A Case Report. [PDF]

Case Rep Dermatol
Bender A, Krönig L.
europepmc   +1 more source

Aberrant Activation of the Hedgehog Pathway in Cutaneous Melanoma: Therapeutic Potential of Pharmacological Inhibitors. [PDF]

Int J Mol Sci
Papaccio F, Kovacs D, Marrapodi R, Caputo S, Migliano E, Melucci E, Scalera S, Cota C, Maugeri-Saccà M, Bellei B.   +9 more
europepmc   +1 more source

Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib

JAAD Case Reports, 2018
Jaeyoung Yoon, MD, PhD, Anthony J. Apicelli, III, MD, PhD, Tricia V. Pavlopoulos, MD   +2 more
doaj   +1 more source

Resistance to SMO Inhibitors in Advanced Basal Cell Carcinoma: A Case Highlighting the Role of Molecular Tumor Profiling. [PDF]

Int J Mol Sci
Papaccio F, Marrapodi R, Eibenschutz L, D'Arino A, Caputo S, Marini A, Scano S, Presaghi A, Cota C, Melucci E, Scalera S, Migliano E, Maugeri-Saccà M, Frascione P, Bellei B.   +14 more
europepmc   +1 more source